Genfit S.A. (NASDAQ:GNFT) Short Interest Update

Genfit S.A. (NASDAQ:GNFT) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 63,400 shares, a growth of 6.0% from the December 15th total of 59,800 shares. Based on an average daily trading volume, of 10,100 shares, the days-to-cover ratio is presently 6.3 days. Approximately 0.1% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of Genfit in a report on Friday, October 11th.

Genfit Trading Up 1.9 %

NASDAQ GNFT traded up $0.07 on Friday, hitting $3.51. 3,904 shares of the stock were exchanged, compared to its average volume of 6,150. The business’s fifty day moving average is $3.97 and its 200 day moving average is $4.49. Genfit has a 52 week low of $3.33 and a 52 week high of $6.42. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.74 and a current ratio of 3.74.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.